Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › doxorubicin

doxorubicin

13 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of doxorubicin

275 trials tracked of doxorubicin: 74 in phase 3 or 4 and 50 with published results. The most-cited published study has 2768 citations.

275Trials tracked
74Phase 3 & 4
0Recruiting
50With published results
Phase distribution
Phase 4 3 Phase 3 71 Phase 2 176 Phase 1 17 Other / NA 8
  1. Phase 3 Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer Completed · 2,768 cited
  2. Phase 3 A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer Completed · 1,053 cited
  3. Phase 3 Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment (FIRM-ACT) Completed · 863 cited
  4. Phase 3 ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas Completed · 721 cited
  5. Phase 3 A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma Completed · 612 cited
  6. Phase 3 Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma Completed · 535 cited
Show 44 more trials
  1. Phase 3 Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma Completed · 421 cited
  2. Phase 3 Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Completed · 417 cited
  3. Phase 3 Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma Completed · 354 cited
  4. Phase 3 SWOG-9704 Chemoradiotherapy and Peripheral Stem Cell Transplantation Compared With Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma Completed · 341 cited
  5. Phase 3 Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer Completed · 336 cited
  6. Phase 3 A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma Completed · 322 cited
  7. Phase 3 A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma Completed · 298 cited
  8. Phase 3 Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma Completed · 268 cited
  9. Phase 3 05-001: Treatment of Acute Lymphoblastic Leukemia in Children Completed · 238 cited
  10. Phase 3 Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Completed · 226 cited
  11. Phase 3 Docetaxel, Doxorubicin (A), Cyclophosphamide (C) (TAC) vs 5-Fluorouracil, A, C (5FAC) Breast Cancer Adjuvant Treatment Completed · 208 cited
  12. Phase 3 Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer Completed · 205 cited
  13. Phase 3 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma Completed · 172 cited
  14. Phase 3 A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer Completed · 164 cited
  15. Phase 3 Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Positive Breast Cancer Completed · 143 cited
  16. Phase 3 Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775]) Completed · 143 cited
  17. Phase 3 Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor Completed · 133 cited
  18. Phase 3 Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma Completed · 126 cited
  19. Phase 3 Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer Completed · 119 cited
  20. Phase 3 Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor Completed · 116 cited
  21. Phase 3 A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer Completed · 114 cited
  22. Phase 3 Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma Completed · 100 cited
  23. Phase 3 Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma Completed · 98 cited
  24. Phase 3 Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations Completed · 84 cited
  25. Phase 3 A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer Completed · 64 cited
  26. Phase 3 Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma Completed · 57 cited
  27. Phase 3 FAC Versus FAC Plus Weekly Paclitaxel as Adjuvant Treatment of Node Negative High Risk Breast Cancer Patients Completed · 57 cited
  28. Phase 3 Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia Completed · 48 cited
  29. Phase 3 Calaspargase Pegol or Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia Completed · 46 cited
  30. Phase 3 Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma Completed · 41 cited
  31. Phase 3 A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM) Completed · 32 cited
  32. Phase 3 Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease Completed · 32 cited
  33. Phase 3 A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer Completed · 27 cited
  34. Phase 3 A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer Completed · 26 cited
  35. Phase 3 A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma Completed · 25 cited
  36. Phase 3 TAC Versus TC for Adjuvant Breast Cancer Completed · 22 cited
  37. Phase 3 Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor Completed · 20 cited
  38. Phase 3 Combination Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Lymphoma Completed · 17 cited
  39. Phase 3 Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin Lymphoma Completed · 17 cited
  40. Phase 3 Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor Completed · 15 cited
  41. Phase 3 Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma Completed · 15 cited
  42. Phase 3 A Study of the Safety of Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Early and Locally Advanced Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Completed · 12 cited
  43. Phase 3 Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer Completed · 10 cited
  44. Phase 4 Effect of Weight on the Population Pharmacokinetic Analysis of Doxorubicin and Cyclophosphamide Completed

Showing the 50 most-cited and recently-updated of 275 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Durvalumab plus chemotherapy shows 35% response in phase II trial for metastatic pulmonary sarcomatoid carcinoma
Pulmonology & Critical Care Phase II
Durvalumab plus chemotherapy shows 35% response in phase II trial for metastatic pulmonary sarcomatoid carcinoma Small study tests drug combination for rare, aggressive lung cancer
A phase II single-arm trial in 20 patients with recurrent/metastatic pulmonary sarcomatoid carcinoma evaluated durvalumab plus doxorubicin/i…
A rare lung cancer drug combo shrank tumors in 35% of patients, offering hope for those with this aggressive disease despite common side eff…
Apr 6, 2026